Genetic Polymorphisms of ABCG2/BCRP on the Transport of Nifedipine to Breast Milk.

Overview

This study aims to investigate the influence of the c.421C>A genetic polymorphism of the ABCG2 / BCRP transporter in the concentration ratio of nifedipine in maternal milk:plasma in hypertensive breastfeeding women attended at the Gynecology and Obstetrics Service of the Medical School of Ribeirão Preto, of the University of São Paulo. Thus, plasma and breast milk samples are being collected from patients in chronic use of the drug (n=30) within 15 to 30 days postnatal.

Full Title of Study: “Influence of Genetic Polymorphisms of ABCG2/BCRP on the Transport of Nifedipine to Breast Milk in Hypertensive Breastfeeding Women.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 1, 2018

Detailed Description

The breast cancer resistance protein (ABCG2/BCRP) human transporter, encoded by the ABCG2 gene, is highly expressed on the human lactating breast. Nifedipine, a known substrate of ABCG2, is used for the treatment of hypertension in pregnancy and during breastfeeding. ABCG2 plays an important role on secreting drugs and xenobiotics into milk. The aim of the present study was to evaluate the effect of ABCG2 c.421C>A on nifedipine breast milk/plasma concentration ratio in hypertensive breastfeeding women. Nineteen hypertensive breastfeeding women treated with 20 mg slow-release nifedipine every 12 hours were investigated. Blood and breast milk samples were collected simultaneously 15-30 days after delivery and at least 15 days after drug treatment, in order to reach drug steady state. All patients were genotyped for ABCG2 c.421C>A using real time-PCR. Nifedipine concentration was determined in plasma and breast milk by high-performance liquid chromatography using UV detection. The comprehension of the variability in the transport of nifedipine to breast milk in hypertensive breastfeeding women will contribute to the evaluation of drug exposure in breast-fed infants to nifedipine and other ABCG2 substrates.

Interventions

  • Procedure: Blood and breast milk sampling
    • At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
  • Drug: Nifedipine
    • Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.

Arms, Groups and Cohorts

  • Active Comparator: Wild homozygous for ABCG2 c.421C>A
    • Chronic hypertensive breastfeeding women (18-45 years old) genotyped as wild homozygous for ABCG2 c.421C>A.
  • Experimental: Variant genotypes for ABCG2 c.421C>A
    • Chronic hypertensive breastfeeding women (18-45 years old) genotyped as heterozygous or mutant homozygous for ABCG2 c.421C>A.

Clinical Trial Outcome Measures

Primary Measures

  • Nifedipine concentration in plasma/milk ratio
    • Time Frame: After reaching steady state (at least 15 days of treatment), samples will be collected before first nifedipine dosing in the morning.
    • The concentration ratio will be determined as (nifedipine concentration in plasma)/(nifedipine concentration in breast milk).

Secondary Measures

  • Nifedipine concentration in plasma
    • Time Frame: After reaching steady state (at least 15 days of treatment), samples will be collected before first nifedipine dosing in the morning.
    • The concentration of nifedipine in plasma determined by HPLC.
  • Nifedipine concentration in milk
    • Time Frame: After reaching steady state (at least 15 days of treatment), samples will be collected before first nifedipine dosing in the morning.
    • The concentration of nifedipine in breast milk determined by HPLC.

Participating in This Clinical Trial

Inclusion Criteria

  • Chronic hypertensive breastfeeding women – Patients being treated with 20 mg slow-release nifedipine every 12 hours for at least 15 days Exclusion Criteria:

  • Patients in use of ABCG2 inhibitors (omeprazole, pantoprazole, ritonavir, saquinavir, imatinib, efavirenz, nicardipine, abacavir, tacrolimus, ciclosporin A, cannabidiol); – Patients who presented nifedipine adverse drug reactions – Patients whose blood pressure normalized after delivery – Patients who interrupted breastfeeding during the study – Patients who did not return to the hospital for the clinical protocol.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Natalia Valadares de Moraes
  • Collaborator
    • Hospital das Clínicas de Ribeirão Preto
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Natalia Valadares de Moraes, Professor of Toxicology – Universidade Estadual Paulista Júlio de Mesquita Filho

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.